Director Wendell Wierenga filed a Form 4 with the SEC on September 1, 2026, reporting the cancellation of common stock, restricted stock units, and stock options in connection with Crinetics Pharmaceuticals, Inc.'s merger with a subsidiary of Vertex Pharmaceuticals Incorporated.

Key Highlights

  • Merger effective date: The merger of Clark Merger Sub, Inc. into Crinetics Pharmaceuticals was reported effective as of September 1, 2026.
  • Merger consideration: Each share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash, without interest and subject to applicable tax withholdings.
  • Common stock canceled: 116,146 shares of common stock were disposed of at $85.00 per share, leaving 5,925 shares; those remaining 5,925 shares (representing RSUs that vested immediately prior to closing) were also then canceled at $85.00 per share, resulting in 0 shares held.
  • RSU cancellation: 5,925 restricted stock units, each representing a contingent right to one share, were vested immediately prior to the effective time and then canceled in exchange for the merger consideration.
  • Stock options canceled: Eight tranches of stock options, totaling 110,080 shares underlying options, were disposed of on September 1, 2026; in-the-money options were converted to cash equal to the difference between $85.00 and the applicable exercise price.
  • Out-of-the-money options: According to the filing, any stock option with a per share exercise price equal to or greater than the merger consideration was canceled for no consideration.
  • Beneficial ownership following transactions: Wierenga's directly held common stock and all derivative securities reported stood at zero following the reported transactions.

Wierenga's Holdings Canceled in Crinetics-Vertex Merger

According to the filing, the transactions stem from an Agreement and Plan of Merger dated July 6, 2026, among Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), Vertex Pharmaceuticals Incorporated, and Clark Merger Sub, Inc., a wholly owned subsidiary of Vertex. At the effective time of the merger on September 1, 2026, Merger Sub merged with and into Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex. All outstanding Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash.

The filing discloses that director Wendell Wierenga held 116,146 shares of common stock disposed of at $85.00 per share, leaving an intermediate balance of 5,925 shares. Those remaining shares corresponded to restricted stock units that, according to the filing, "immediately prior to the Effective Time...became immediately vested in full" and were then canceled and converted into the right to receive the merger consideration of $85.00 per unit, less applicable tax withholding. After both transactions, Wierenga's direct common stock holding stood at zero.

In Table II, the filing reports the cancellation of eight tranches of stock options with exercise prices ranging from $18.29 to $44.71 per share and expiration dates between June 21, 2029 and June 18, 2036. The filing explains that each in-the-money option was canceled and converted into the right to receive cash equal to the difference between $85.00 and the applicable per share exercise price, with those per-share cash amounts reported in Column 8 of the filing. All reported stock option positions were reduced to zero following the transactions. The filing was signed by Tobin Schilke as attorney-in-fact on September 1, 2026.

What Was Disclosed

Director Wendell Wierenga reported the cancellation of 116,146 common shares, 5,925 RSUs, and eight tranches of stock options in connection with Crinetics Pharmaceuticals' merger with a Vertex Pharmaceuticals subsidiary, effective September 1, 2026, at $85.00 per share in cash.